Neurology · Kansas City, KS
Neurology studies in Kansas City, KS
28 recruiting studies have a site in Kansas City.
28 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2/Phase 3
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Biohaven Therapeutics Ltd.
- Location
- Kansas City, KS + 24 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC
- Location
- Kansas City, KS + 18 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi
- Location
- Kansas City, KS + 31 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Kansas City, KS + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
- Location
- Kansas City, KS + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
- Location
- Kansas City, KS + 44 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
AllRock Bio, Inc.
- Location
- Kansas City, KS + 10 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Kansas City, KS + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Appello Pharmaceuticals, Inc.
- Location
- Kansas City, KS + 29 other US sites
- Eligibility basics
- Ages 30–80
- RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Neuron23 Inc.
- Location
- Kansas City, KS + 43 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Celgene
- Location
- Kansas City, KS + 13 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH
- Location
- Kansas City, KS + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Kansas City, KS + 27 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 3
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Kansas City, KS + 17 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 2/Phase 3
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Janssen Research & Development, LLC
- Location
- Kansas City, KS + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Kansas City, KS + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Kansas City, KS + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2/Phase 3
A Study of Buntanetap in Participants With PD
Annovis Bio Inc.
- Location
- Kansas City, KS + 26 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 1/Phase 2
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Tr1X, Inc.
- Location
- Kansas City, KS + 7 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Novartis Pharmaceuticals
- Location
- Kansas City, KS + 42 other US sites
- Eligibility basics
- Ages 40–70
- RecruitingPhase 1/Phase 2
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
UniQure Biopharma B.V.
- Location
- Kansas City, KS + 15 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
BlueRock Therapeutics
- Location
- Kansas City, KS + 33 other US sites
- Eligibility basics
- Ages 45–75
- RecruitingPhase 4
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
Impax Laboratories, LLC
- Location
- Kansas City, KS + 22 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment
BrainQ Technologies Ltd.
- Location
- Kansas City, KS + 6 other US sites
- Eligibility basics
- Ages 22–80
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.